Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

The same career FDA bureaucrat who crowed about “following the science” to discredit President Trump has approved a failed Alzheimer’s drug.

The center will foster communication between CDER staff and clinical trial stakeholders, with the goal of making it easier for sponsors to innovate.

The Center for Drug Evaluation and Research has seven robotic process automation projects in development as it works to free up staff for its core science mission. An agency within the Food and Drug ...

The top drug regulator at the FDA is retiring in July, as departures of senior leaders mount.

The Food and Drug Administration could roll out a new logo as soon as this year for companies to stamp on the packaging of "healthy" foods they make, aimed at clearing up confusion on what ...

The FDA is handing back the reins to the FDA's Center for Drug Evaluation and Research to Janet Woodcock (photo), who had formerly headed the division for 10 years.

The FDA’s Center for Drug Evaluation and Research (CDER) approval of aducanumab (Aduhelm) for Alzheimer’s is the latest in a series of decisions where the FDA appeared to bow to politics and ...

On April 15, 2024, the US Food & Drug Administration (FDA) announced the establishment of the Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI). C3TI will ...

The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has announced the launch of a new hub focused on promoting innovation in clinical trials. The CDER outlined ...

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.